BioPharmSignal logoBioPharmSignal

Biotech News

Aligos Therapeutics to Present at the Cantor Global Healthcare Conference

Aligos Therapeutics (ALGS)Aligos TherapeuticsConference / presentation

SOUTH SAN FRANCISCO, Calif., Sept. 02, 2026 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS), a clinical stage biopharmaceutical company focused on improving patient outcomes through best-in-class therapies for liver and viral diseases, today announced that members of management will

Related news

ALGSAligos Therapeutics2026-05-13 06:05 EST

Aligos Therapeutics Announces Ten Abstracts Accepted for Presentation at the EASL Congress 2026

MLYSMineralys Therapeutics2026-08-26 12:00 EST

Mineralys Therapeutics to Participate in the Wells Fargo 21st Annual Healthcare Conference

MLYSMineralys Therapeutics2026-06-08 20:05 EST

Mineralys Therapeutics to Participate in the Goldman Sachs 47th Annual Global Healthcare Conference

LXRXLexicon Pharmaceuticals2026-05-28 12:30 EST

Lexicon Pharmaceuticals to Present at the 2026 Jefferies Global Healthcare Conference

CVRXCVRx2026-05-27 20:30 EST

CVRx to Present at the Goldman Sachs 47th Annual Global Healthcare Conference

VANIVivani Medical2026-05-28 12:30 EST

Vivani Medical CEO Adam Mendelsohn to Present at the Jefferies Global Healthcare Conference on June 4, 2026

MNKDMannKind2026-05-27 20:00 EST

MannKind to Present at Jefferies Global Healthcare Conference

ALTAltimmune2026-09-03 12:00 EST

Altimmune to Participate in the Wells Fargo 21st Annual Healthcare Conference

BLTEBelite Bio2026-06-02 12:00 EST

Belite Bio to Participate in the Goldman Sachs 47th Annual Global Healthcare Conference

BLTEBelite Bio2026-04-27 12:00 EST

Belite Bio Announces Oral Presentation at the Retinal Therapeutics Innovation Summit

View all latest news

Aligos Therapeutics

Liver and Viral Diseases Aligos Therapeutics develops small-molecule and oligonucleotide therapies for liver and viral diseases. Its lead clinical effort targets chronic hepatitis B through suppression of viral antigen production. Pevifoscorvir Sodium Pevifoscorvir sodium is an antisense oligonucleotide designed to reduce hepatitis B...

Recent company news

ALGSAligos Therapeutics2026-09-02 12:00 EST

Aligos Therapeutics to Present at the Cantor Global Healthcare Conference

ALGSAligos Therapeutics2026-08-12 20:05 EST

Aligos Therapeutics Announces First Participant Dosed in the Phase 1 Study of its Potentially Best-in-Class Antisense Oligonucleotide ALG-170675 by its Partner Amoytop in China

ALGSAligos Therapeutics2026-08-06 12:00 EST

Aligos Therapeutics Reports Recent Business Progress and Second Quarter 2026 Financial Results

ALGSAligos Therapeutics2026-07-30 12:00 EST

Aligos Therapeutics to Announce 2nd Quarter 2026 Financial Results on August 6, 2026

ALGSAligos Therapeutics2026-07-13 12:00 EST

Aligos Therapeutics Announces the Completion of Enrollment in the Phase 2 B-SUPREME Study of Pevifoscorvir Sodium Under Development for the Treatment of Chronic HBV Infection

Stock data

Close
5.17 USD
Market cap
32.49M USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States